Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Increases By 232.0%

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 540,900 shares, a growth of 232.0% from the February 13th total of 162,900 shares. Approximately 81.8% of the company’s stock are short sold. Based on an average daily volume of 1,740,000 shares, the short-interest ratio is currently 0.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of TransCode Therapeutics in a report on Thursday.

TransCode Therapeutics Stock Up 4.8 %

NASDAQ RNAZ opened at $0.78 on Friday. TransCode Therapeutics has a 1-year low of $0.65 and a 1-year high of $66.33. The firm’s fifty day simple moving average is $5.54 and its 200-day simple moving average is $237.59.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.